Thorazine (Chlorpromazine) Dosing
For acute agitation and psychosis, start chlorpromazine at 12.5-25 mg intramuscularly every 4-12 hours, with typical effective doses ranging from 37.5-150 mg/day parenterally, or 25-100 mg every 4-12 hours rectally (75-300 mg/day). For oral dosing in chronic management, moderate doses of 300-600 mg/day chlorpromazine equivalent are adequate for most patients, with evidence showing no benefit and increased extrapyramidal side effects at higher doses 1, 2, 3.
Acute Management Dosing
Intramuscular Administration
- Starting dose: 12.5-25 mg IM every 4-12 hours
- Alternative: 3-5 mg/hour IV infusion
- Usual effective range: 37.5-150 mg/day parenterally 1
Rectal Administration
- Starting dose: 25-100 mg every 4-12 hours
- Usual effective range: 75-300 mg/day 1
For Insomnia/Sedation
- Bedtime dose: 25-50 mg PO at bedtime 4
Chronic/Maintenance Dosing
The evidence strongly supports moderate dosing (300-600 mg/day chlorpromazine equivalent) for chronic schizophrenia management. Research from the 1980s established that doses above this range provide no additional benefit while significantly increasing side effects, yet adoption of evidence-based dosing was delayed for years 3, 5, 6.
Key Dosing Principles:
- Optimal range: 300-600 mg/day oral equivalent for most patients
- Single daily dosing: 300 mg at bedtime is as effective as divided doses (100 mg three times daily) with potentially less daytime sedation 7
- Maintenance therapy: No dose-response relationship exists between 100-2000 mg/day for relapse prevention; median effective dose is 310 mg/day 8
Critical Safety Considerations
Cardiovascular Monitoring
When administering IV chlorpromazine, infuse at a rate of 1 mg/minute to minimize hypotension risk. Recent data show this rate produces only modest MAP decreases (median 88 to 83 mm Hg) without clinically significant hemodynamic instability 9.
Extrapyramidal Symptoms
Higher doses dramatically increase extrapyramidal symptom risk. When comparing low-dose (≤400 mg/day) to medium-dose (401-800 mg/day), significantly more patients on medium doses experienced extrapyramidal symptoms (RR 0.47,95% CI 0.30-0.74). High doses (>800 mg/day) showed even greater risk (RR 0.43,95% CI 0.32-0.59) 3.
Blood Monitoring
For long-term therapy, monitor CBC frequently during initial months due to leukopenia/agranulocytosis risk. Discontinue immediately if WBC declines without other causative factors 10.
Special Populations
Elderly/Dementia Patients
Chlorpromazine should not be used as first-line therapy in dementia patients due to significant cholinergic, cardiovascular, and extrapyramidal side effects, plus 50% risk of tardive dyskinesia after 2 years of continuous use. Consider only for severe, distressing symptoms with imminent risk of harm, preferably after specialist consultation 11, 12.
Pediatric Agitation
In critically ill children with refractory agitation, chlorpromazine demonstrated effectiveness with median age 14.5 months. Mean CAPD scores improved from 12 to 8.9 (p=0.0021) within 24 hours without significant adverse effects 13. However, 38% of administrations resulted in drug-drug interactions and 35% caused side effects, suggesting careful patient selection 14.
Common Pitfalls
- Avoid dose escalation beyond 600 mg/day in chronic management—no additional efficacy but substantially increased side effects
- Do not combine with high-dose olanzapine—fatalities reported 2
- Discontinue 48 hours before myelography with metrizamide and do not resume for 24 hours post-procedure 10
- Reduce CNS depressant doses by 1/4 to 1/2 when co-administering chlorpromazine 10
- Monitor for orthostatic hypotension, particularly with IV/IM routes and in elderly patients 1, 2